Novel endogenous protein-based strategies to inhibit clinically relevant bacterial AB-type toxins including pertussis toxin
-
By
-
Stefanie Lietz
-
Holger Barth
-
April 17, 2026
-
Clinical Scorecard: Innovative Approaches Using Endogenous Proteins to Block Clinically Significant AB-Type Toxins, Including Pertussis Toxin
At a Glance
| Category | Detail |
|---|
| Condition | Pertussis (Whooping Cough) |
| Key Mechanisms | AB-type toxins with A-subunit (enzymatic activity) and B-subunit (binding/translocation) disrupt cellular functions. |
| Target Population | Individuals at risk for pertussis, particularly infants and adolescents. |
| Care Setting | Clinical settings managing infectious diseases and vaccination programs. |
Key Highlights
- Pertussis toxin (PT) is a major virulence factor of Bordetella pertussis.
- Recent outbreaks of pertussis despite vaccination efforts indicate waning immunity.
- Severe cases of pertussis can lead to hospitalization and complications such as pneumonia and seizures.
- Novel therapeutic options targeting AB-type toxins are urgently needed due to antibiotic resistance.
Guideline-Based Recommendations
Diagnosis
- Increased testing for pertussis in symptomatic patients, especially in vulnerable age groups.
Management
- Early antibiotic treatment is crucial for effective management of pertussis.
Monitoring & Follow-up
- Monitor vaccination coverage and case numbers to assess outbreak risks.
Risks
- Increased incidence of pertussis in unvaccinated populations and waning immunity in vaccinated individuals.
Patient & Prescribing Data
Infants under three months, adolescents, and unvaccinated individuals.
Antibiotics eliminate toxin-producing bacteria but do not neutralize secreted toxins.
Clinical Best Practices
- Implement vaccination programs to improve coverage and prevent outbreaks.
- Educate healthcare providers on the importance of early diagnosis and treatment.
References
